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Abstract
Background: Hepatitis C virus (HCV) Core protein is thought to trigger activation of multiple signaling pathways
and play a significant role in the alteration of cellular gene expression responsible for HCV pathogenesis leading to
hepatocellular carcinoma (HCC). However, the exact molecular mechanism of HCV genome specific pathogenesis
remains unclear. We examined the in vitro effects of HCV Core protein of HCV genotype 3a and 1a on the cellular
genes involved in oxidative stress and angiogenesis. We also studied the ability of HCV Core and Cox-2 siRNA
either alone or in combination to inhibit viral replication and cell proliferation in HCV serum infected Huh-7 cells.
Results: Over expression of Core gene of HCV 3a genotype showed stronger effect in regulating RNA and protein
levels of Cox-2, iNOS, VEGF, p-Akt as compared to HCV-1a Core in hepatocellular carcinoma cell line Huh-7
accompanied by enhanced PGE2 release and cell proliferation. We also observed higher expression levels of above
genes in HCV 3a patient’s blood and biopsy samples. Interestingly, the Core and Cox-2-specific siRNAs down
regulated the Core 3a-enhanced expression of Cox-2, iNOS, VEGF, p-Akt. Furthermore, the combined siRNA
treatment also showed a dramatic reduction in viral titer and expression of these genes in HCV serum-infected
Huh-7 cells. Taken together, these results demonstrated a differential response by HCV 3a genotype in HCV-
induced pathogenesis, which may be due to Core and host factor Cox-2 individually or in combination.
Conclusions: Collectively, these studies not only suggest a genotype-specific interaction between key players of
HCV pathogenesis but also may represent combined viral and host gene silencing as a potential therapeutic
strategy.
Background
An estimated 3% of the world’s population is chronically
infected with Hepatitis C virus (HCV) which is the main
cause of liver fibrosis and cirrhosis, often leading to
HCC (hepatocellular carcinoma) in a substantial number
of patients. Almost 10 million people in Pakistan are liv-
ing with HCV [1,2]. The most prevalent HCV genotype
in Pakistan is 3a followed by 1a [3]. HCV virion is
enveloped and has a positive strand genome comprising
9.6 kb RNA which is processed by cellular and viral pro-
teases into 10 viral proteins, Core, E1, E2, p7 (structural
proteins), NS2, NS3, NS4a, NS4b, NS5a and NS5b (non-
structural proteins). Although specific mechanisms by
which HCV disease progresses remains unknown, direct
interaction of specific viral proteins with host cell sys-
tem has shown to be accounted for some of its patho-
physiological profile of HCV patients [4].
Besides nucleocaspid formation, HCV Core protein, in
particular, also modulates gene transcription, cell prolif-
eration, cell death and interferes with metabolism lead-
ing to oxidative stress, liver steatosis and eventually
HCC. Oxidative stress has emerged as a key contributor
in the development and progression of HCV-induced
pathogenesis of liver [5,6]. Several factors might contri-
bute to oxidative stress associated with HCC, as HCV
Core and NS5a proteins, which are able to up-regulate
Cox-2 expression; a key player of oxidative stress in
hepatocytes derived cells [7]. The expression of Cox-2
in HCC was found to correlate with the levels of several
key molecules implicated in carcinogenesis such as
iNOS (induced nitric oxide synthase), VEGF (vascular
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Cox-2 have carcinogenic effects achieved either directly
or by producing mediator that regulate cellular growth
[10]. Cox-2 can induce angiogenesis growth factors via
VEGF in HCV associated HCC [9,11,12]. A number of
other inflammatory mediators including nitric oxide
(NO), Cox-2, and prostaglandin E2 (PGE2) in cultured
hepatocellular carcinoma cells also stimulate VEGF [11].
Cox-2 activates Akt in human HCC via a p13-kinase-
dependent mechanism [13], it acts as an important
signal mediator, which regulates cell survival and prolif-
eration [14,15]. Despite several studies, mechanisms
involved in HCV-associated pathogenesis are not com-
pletely understood; it may vary as a function of viral
genotype [16].
Very few studies have been undertaken to evaluate the
role of HCV Core protein of genotype 3a and 1a in
HCV induced pathogenesis. In this study, we selected
Huh-7 cells as culture model system for the transient
transfection using HCV 3a and 1a Core genes and viral
load analysis using HCV-infected serum as inoculum.
We found a greater effect of HCV Core of genotype 3a
on the expression levels of Cox-2, iNOS, VEGF, p-Akt
in transiently expressing Core protein and in serum-
infected Huh-7 cells as well as in patient’s blood and
liver biopsies samples. Although, HCV Core protein is
highly conserved between different genotypes, we
observed differences in the HCV Core region of 1a and
3a and speculate that these differences may differentially
regulate hepatic pathogenesis in HCV infected
individuals.
HCV RNA is highly susceptible to RNAi-induced
suppression, as many investigators have reported the
inhibition of HCV RNA levels by targeting different
genes using RNAi. In our previous study, we used
s i R N Aa g a i n s tH C V3 aC o r ea n di n h i b i t e di t se x p r e s -
sion not only in transiently transfected cells but also in
serum infected Huh-7 cells [17]. Here, we used siRNA
against Core and Cox-2 genes either alone or in com-
bination with HCV 3a Core gene-transfected and
serum-infected Huh-7 cells to further study HCV-
induced pathogenesis. We observed additional inhibi-
tory effect of HCV Core and Cox-2 silencing on the
expression levels of genes involved in HCV pathogen-
esis, suggesting a possible virus host interaction among
these, moreover, reduction of viral titer may also
represent potential combinational therapeutic approach
against HCV infection.
Results
Role of HCV Core in HCV induced pathogenesis
HCV 1a and 3a Core genes were cloned into pCR3.1/
FLAG tag (Figure 1A). The amino acid sequence com-
parison showed that 3a Core protein has 90% similarity
to 1a Core protein and 98% similarity to their consensus
sequences (Figure 1B). We observed several nucleotide
differences in both genotypes when compared with lit-
erature. These changes are N in 1a at position 4 and L
in 3a, Q in 1 and H in 3 at position 8, N in 1 I in 3a at
position 16 and T in 1a and N in 3a at position 70. The
other reported difference is YATG in 1a and FATG in
3a at position 164 amino acid (Figure 1B). In order to
observe whether 1a and 3a differentially regulate the
expression of Cox-2, iNOS, p-Akt and VEGF, Huh-7
cells were transiently transfected with or without 0.4 μg
HCV genotype 1a and 3a Core expressing plasmids for
48 hrs. The mRNA expression levels of Cox-2, iNOS,
and VEGF genes were determined using Real-Time
PCR. As shown in Figure 1C, HCV 3a Core induced the
expression of Cox-2, iNOS and VEGF genes at signifi-
cantly higher levels as compared to HCV 1a Core gene.
Up-regulated levels for Cox-2, iNOS and VEGF were
4.1, 2.4 and 2.8-fold, respectively, with HCV 3a Core
w h e r e a s ;H C V1 aC o r ei n d u c e dC o x - 2( 1 . 3 - f o l d ) ,i N O S
Figure 1 HCV Core expression plasmids and protein sequences
comparison of HCV genotype 1a and 3a. A) Schematic diagram
of HCV Core expression plasmid illustrating the FLAG tag sequences
having ATG start site and with HCV3a and 1a Core (1-573 bp)
sequence insertion into mammalian expression plasmid pCR3.1. The
CMV promoter and BGHpA regions of pCR3.1 are also shown. (B)
Amino acid sequence comparison of HCV Core 1a and 3a clones.
Comparison of full predicted amino acid sequence of HCV Core
isolates in our study against a consensus genotype 3a clone
(3aCON) and 1a (1aCON) from the HCV sequence database,
performed using the ClustalW program. Sequences different from
consensus are boldface and underlined. Differences in the individual
amino acid Core 1a and Core 3a are highlighted. Asterisks at the
bottom of a sequence comparison indicate complete identity at
that position.
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(Figure 2A). Similar results were obtained with HCV
1a and 3a infected patient’s PBMCs. Up-regulation of
genes in HCV 3a infected blood was as follow: Cox-2
(4.19-fold), iNOS (3.4-fold), and VEGF (3.22-fold) as
compared to HCV 1a infected patient’s blood and nor-
mal samples (Figure 2B). In HCV 3a infected biopsy
samples, the expression levels for these genes were in
this fashion: Cox-2 (4.97-fold), iNOS (5.08-fold), and
VEGF (6.49-fold) compared with normal samples (Fig-
ure 2C). Cell lysates from Core transfected Huh-7 cells
were examined by Western blot analysis using Core,
Cox-2, VEGF, and p-Akt specific antibodies. Significant
increase (p < 0.001) in the protein expression levels in
HCV 3a genotype was observed as compared to HCV
1a (Figure 2D).
In order to determine the effect of HCV Core gene
expression on cell proliferation, PGE2 levels were
determined by Biotrak Prostaglandin E2 Enzyme
Immunoassay system. HCV Core protein of both geno-
types significantly increased the production of PGE2
more with HCV 3a Core than HCV 1a in Huh-7 cells
(Figure 3A). Core induced cell proliferation was also
determined through MTT cell proliferation assay.
These results mirrored those observed with PGE2, a
significant enhanced cell proliferation observed with
both genotypes. HCV 3a genotype has greater effect
compared with HCV 1a genotype (Figure 3B). Taken
Figure 2 HCV 3a Core gene shows higher induction of Cox-2, iNOS, VEGF and p-Akt compared to HCV 1a Core gene. (A) Comparison of
gene expression of Cox-2, iNOS and VEGF in Huh-7 cells transiently transfected with HCV Core 1a (C1a), 3a (C3a) and pCR3.1 plasmid alone as
mock (M) samples (0.4 μg DNA/well of each plasmid). After 48 hrs incubation, relative gene expression levels were determined. (B) Comparison
of expression of Cox-2, iNOS, and VEGF genes expressed as relative fold induction in HCV 1a and 3a infected patient’s blood samples verses
normal. (C) Expression of Cox-2, iNOS and VEGF genes in HCV 3a genotype infected liver biopsies verses normal. (D) The protein expression
levels were determined by Western blot analysis of Huh-7 cell lysates transfected with HCV Core vectors 1a, 3a and effect on Cox-2, VEGF, p-Akt
and GAPDH using specific antibodies. Blots were also normalized by measuring the amount of GAPDH (histogram). Bars are mean of optical
density ratio of each group.* p < 0.001 verses control and Core 1a. GAPDH gene was used as internal control for normalization in Real-Time PCR
and in Western blotting. All experiments were performed in 3 independent experiments having triplicate samples in each.
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ment of HCV Core in the induction of Cox-2, iNOS,
p-Akt and VEGF host genes at RNA/protein levels in
Huh-7 cells. Their high expression in HCV 3a infected
patient’s samples and cell proliferation assay/PGE2
levels further supported genome-specific role of HCV
in its pathogenesis.
Effect of HCV 3a Core-specific siRNA on the expression of
Cox-2, iNOS and VEGF genes
HCV 3a Core showed significantly higher induction levels
as compared to HCV 1a Core. Therefore, we utilized gene
silencing against HCV 3a Core to investigate its involve-
ment in the regulation of Cox-2, iNOS, p-Akt and VEGF
genes. Transient transfection of two in-vitro transcribed
siRNAs Csi27 and Csi352 in Huh-7 cells after 48 hrs
showed a dramatic reduction of mRNA expression levels
of HCV 3a Core gene in a dose-dependent manner. Maxi-
mum inhibition of 3-fold and 2-fold was observed for
Csi27 and Csi352 at 40 μM concentrations, respectively,
when compared with scramble siRNA (Figure 4A). The
effect of HCV 3a Core siRNAs on mRNA expression levels
of Cox-2, iNOS, VEGF genes in Huh-7 cells was also
determined. Although, both Csi27 and Csi352 siRNAs
decreased the expression levels of all four genes, Csi27
showed dramatic reduction for Cox-2 (2.5-fold) gene,
whereas, expression of iNOS, and VEGF was reduced to 1
fold, respectively (Figure 4B). Complementary to reduced
mRNA levels, HCV 3a Core protein expression was also
inhibited 90% and 76% with Csi27 and Csi352 siRNA,
respectively. These siRNA also inhibited protein expres-
sion levels of Cox-2 (85% with Csi27 and 70% with
Csi352) and VEGF (75% with Csi27 and 65% with Csi352)
as compared to control scramble siRNA (Figure 4C). Simi-
larly, the expression of Cox-2 gene was reduced to the
basal levels with its own siRNA, whereas, Cox-2 siRNA
treatment decreased the expression levels of iNOS and
VEGF genes to 2 and 3-fold, respectively (Figure 5A).
Inhibition of genes with combined silencing of HCV 3a
Core and host Cox-2 genes
We further investigated whether HCV Core 3a is regu-
lating gene expression directly or via Cox-2. HCV Core
3a transfected cells were treated with Core and Cox-2
specific or scrambled siRNAs either alone or in combi-
nation. Real-Time PCR results showed that Core-
induced expression of Cox-2, iNOS and VEGF genes
was markedly reduced to 3, 2 and 1.5 fold respectively,
after co-treatment with HCV 3a Core and Cox-2 speci-
fic siRNA (Figure 5A). A dramatic reduction was
observed at protein levels for Cox-2, VEGF and p-Akt
in cells treated with Core and Cox-2 siRNA in combina-
tion (Figure 5B). The over all mechanism of regulation
of oxidative stress by HCV Core and Cox-2 has been
shown in Figure 6.
Suppression of viral load and gene expression by HCV
Core and Cox-2 siRNA in Huh-7 cells
Additionally, the efficacy of siRNA against HCV 3a Core
and Cox-2 genes alone or in combination was evaluated
in serum-infected Huh-7 cells. A remarkable suppres-
sion of HCV RNA was observed up to 92% with HCV
3a Core-siRNA, 83% with Cox-2 siRNA and 95% with
combination of both siRNAs (Figure 7A). Both siRNA
either alone or in combination inhibited the RNA
expression levels of Cox-2, iNOS and VEGF. These
results indicate that siRNA against HCV 3a Core and
Cox-2 genes decreased the mRNA expression levels of
Cox-2 (2-fold), iNOS (1.5-fold) and VEGF (1.8-fold)
genes (Figure 7B). Additionally, there was significant
reduction at protein levels of Cox-2, VEGF and p-Akt in
cells treated with Core and Cox-2 siRNA (Figure 7C).
Figure 3 Enhanced expression of PGE2 and cell proliferation in
Core transfected Huh-7 cells. (A) Prostaglandin E2 production in
response to HCV 1a and 3a Core transfected Huh-7 cells were
measured with Biotrak Prostaglandin E2 Enzyme Immunoassay
system. (B) MTT assay shows that HCV 3a Core significantly
increased the proliferation of Huh-7 cells as compared to mock and
Core 1a transfected cells, observed at 570 nm wavelength. All
experiments were performed in 3 independent experiments having
triplicate samples in each. Error bars indicate, mean S.D, *p < 0.01
verses mock.
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HCV-induced pathogenesis like liver injury, insulin
resistance and steatosis may be genotype specific. A
high rate of HCV associated HCC prevalence in Asia
has been observed with genotype 3 followed by 1
responsible for most of the cases in Pakistan [3,18-20].
Several studies have been conducted to unravel the
HCV pathogenesis related to genotype 1 and 2 [20,21].
However, no studies related to role of HCV genotype 3a
in oxidative stress are currently available. In this study,
we compared the expression of HCV genotype 1a and
3a in oxidative stress.
Our results showed a significantly higher expression of
Cox-2, iNOS, and VEGF genes in HCV 3a patient blood
as compared with HCV 1a genotype at mRNA levels.
We observed the significant stimulation of Cox-2, iNOS,
and VEGF in HCV 3a infected patients biopsy samples
compared to normal. Unfortunately, we were unable to
compare the expression level of these genes in HCV
infected 1a patients biopsy samples because of non-
availability of 1a liver biopsy samples as very few
patients agreed to underwent liver biopsy. The expres-
sion levels of Cox-2, iNOS, p-Akt and VEGF are posi-
tively correlated in cultured cells and in human liver
cancer tissues suggesting their involvement in chronic
liver diseases. NO and Cox-2 have carcinogenic effects
achieved either directly or by producing mediators that
regulate cellular growth [9,10]. Over expression of Cox-
2 induces angiogenesis through increased levels of
proinflammatory molecule PGE2 which in return acti-
vates VEGF [22] and Akt that promote the growth of
human HCC cells [9,13].
HCV Core protein is involved in a whole array of host
cell functions including signal transduction and
Figure 4 HCV 3a Core-specific siRNA inhibit expression of genes involved in HCV pathogenesis. Huh-7 cells were transfected with HCV 3a
Core expression vector or mock along with or without siRNA. (A) Dose dependent mRNA expression of HCV 3a Core gene as a result of 10 μM,
20 μM and 40 μM of siRNAs for 48 hrs. Cells were harvested and relative RNA levels in PCR Csi27 and Csi352 siRNAs tranfected cells were
determined using semi-quantitative PCR. Expression levels for mock-transfected (M), HCV 3a Core expression plasmid (C), scramble siRNA (SC)
and GAPDH are also shown. (B) Silencing effect of HCV 3a Core gene on the RNA expression levels of cellular genes (Cox-2, iNOS and VEGF) 48
hrs post transfection on Real-Time PCR using gene specific primers in comparison to mock was performed. GAPDH was used as internal control.
Three independent experiments were performed having triplicate samples. Error bars indicate, mean S.D, *p < 0.001 verses Core. (C) Silencing of
HCV 3a Core gene and its effect on Cox-2 and VEGF protein level using specific antibodies were determined by Western blot analysis after 48
hrs transfection in Huh-7 cells with GAPDH as internal control. Bars are mean of optical density ratio of each group.* p < 0.001 verses control
and Core 3a.
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reported that HCV Core protein regulates Cox-2 expres-
sion in hepatocytes and causes oxidative stress leading
to HCC [7]. In the present study, Core protein of HCV
3a was found to enhance the expression of cellular
genes Cox-2, iNOS, p-Akt and VEGF at mRNA and
protein at higher level compared to Core gene of HCV
1a in Huh-7 cell line. The production of PGE2 was
assayed in HCV 1a and 3a transfected cells and results
indicated that the level of PGE2 was increased in HCV
3a Core transfected cells as compared to 1a. Further-
more, cell proliferation was found to be enhanced in
Core 3a transfected cells because of Core-induced Cox-
2 activation of PGE2 release at 48hrs post transfection
(Figure 3). Our results support the observation that
enhanced synthesis of Cox-2 as a consequence of Core
3a induced PGE2 that stimulates the release of proan-
giogenic factor VEGF. VEGF production is regulated by
COX-2, suggesting a promoting role of COX-2 in tumor
angiogenesis through the COX-2/VEGF system [[20,23]
and [24]].
Many studies have reported that substitutions in the
HCV Core region results in enhanced insulin resistance,
steatosis, oxidative stress and hepatocellular carcinoma
[25,26]. Amino acid substitution at the sequence YATG
(1b) and FATG (3a) of HCV Core gene was found to be
important for FAS activation in genome specific manner
[21]. Previously, Hourioux et al., (2007) showed a
greater involvement of these HCV 3a amino acid
Figure 5 Combined effect of Cox-2 and HCV 3a Core siRNAs on
Cox-2, iNOS, VEGF and p-Akt gene expression. (A) Huh-7 cells
were transfected with HCV 3a Core expression vector (C) or mock-
treated (M) along with or without siRNAs (Csi27 and COXsi) alone or
in combination (Csi27+COXsi) for 48 hrs. Total RNA was quantified
by Real-Time PCR and is shown as fold induction for Cox-2, iNOS
and VEGF genes using their gene specific primers. (B) Western blot
analysis of Huh-7 cells treated with and without Core, Cox-2 and
combined siRNA was carried out using specific antibodies. Three
independent experiments with triplicate determinations were
performed. Error bars indicate mean S.D, * p < 0.01 verses serum 1a.
Figure 6 HCV Core protein affects on the cellular genes
involved in oxidative stress, apoptosis, cell survival and
angiogenesis. Schematic diagram illustrating the role of HCV Core
on cellular genes. In HCV, normal angiogenesis process can be
malignant by deregulation of genes involved in this pathway. HCV
Core protein up-regulates NFKB, which further up-regulates iNOS
and COX-2 pathways, and inhibit apoptosis by blocking bad and
caspase pathway. COX-2 up-regulation leads to apoptosis inhibition
via VEGF pathway. VEGF can trigger angiogenesis either by iNOS or
AKT activation. AKT singling also up-regulates AR and inhibit BAD
and Caspase9 that leads to angiogenesis via cell survival. AKT also
have direct impact on iNOS regulation that also escorts to
angiogenesis. We corroborated that using siRNA against Core, or
Cox-2 either alone or in combination can block angiogenesis
directly or via Cox-2 reduced expression. PLC, PhosphoLipase; DAG,
diacylglycerol; PKC, protein kinase C; iNOS, inducible nitric oxide
synthase; NO, nitric oxide; VEGF, vascular endothelial growth factor;
PGE2, prostaglandin E2; COX-2, cyclooxygenase-2; NFKB, nuclear
factor kappa-B; P13K, phosphoinositide-3-kinase; PIP3,
phosphatidylinositol 3,4,5-trisphosphate; PRAS40, proline-rich Akt
substrate of 40 kDa; AR, Aldose reductase; BAD, Bcl-XL/Bcl-2-
associated death promoter; CASPASE9, apoptosis-related cysteine
peptidase.
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ture system [27]. Furthermore, Jhaveri et al., (2008)
reported that amino acid substitution of HCV 3a Core
(LLSCLIH) at 182 and 186 positions are associated with
HCV induced steatosis [28]. Amino acid substitution in
HCV Core gene has different impact in hepatic steatosis
and oxidative stress in chornic HCV patients. Tachi et
al (2009) has reported that in HCV genotype 1b infected
patients with hepatic steatosis, there was amino acid
substitution ‘Q’ at 70 while in patients without steatosis
Arg was present. He also reported that Met91aa of Core
region in patients infected with HCV 1b have high oxi-
dative stress measured through the level of 8-hydroxy-
20-deoxyguanosine as compared in those with Leu91aa
[20]. Mann et al., observed that the divergence in Core
9-11 amino acid at genotype level modulate the NF-kB
activation, a transcription factor which play important
factor in inflammation and liver injury. Core encoding
RKP failed to activate NF-kB signaling in vitro while
NF-kB activation by Core encoding RQT does not differ
from control RKT Core [29]. Steatosis and oxidative
stress are interlinked and arise due to accumulation of
triglyceride rich lipids in cytoplasm [4,30]. We have also
observed the same amino acid variations that were pre-
viously reported plus few other substitutions in HCV 3a
Core sequence in comparison with 1a (Figure 1B).
Although there is 90% amino acid sequence similarity,
however, we observed few sequence differences too.
These changes are N in 1a at position 4 and L in 3a, Q
i n1a n dHi n3a tp o s i t i o n8 ,Ni n1Ii n3 aa tp o s i t i o n
Figure 7 Silencing of Cox-2 and HCV 3a Core genes either alone or in combination and reduction of viral titer in Huh-7 cells infected
with HCV 3a sera. (A) After 3 days of post infection of Huh-7 cells with HCV 3a sera (Ser 3a), cells were transfected with siRNAs (Csi27 and
COXsi) either alone or in combinations (Csi27+COXsi). Data are expressed as mean percent viral load of non-siRNA treated samples. (B) Gene
expression analysis was performed using Real-Time PCR. The effect of siRNA on the induction of genes in serum infected and siRNA treated
Huh-7 cells. Data are expressed as relative fold reduction to mock sample for Cox-2, iNOS and VEGF genes. (C) The effect of siRNA on protein
expression levels of Cox-2, VEGF, p-Akt and GAPDH were determined after 72 hrs post infection with HCV 3a Serum by Western blot analysis
from Huh-7 cell lysates using specific antibodies. Three independent experiments with triplicate determinations were performed. Error bars
indicate, mean S.D. *#p < 0.001 verses Csi27. * p < 0.001 verses Ser3a.
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we speculate that these sequences may play a role in dif-
ferentially regulating genes involved in oxidative stress
leading to HCC. Vidali et al., found a relationship
between oxidative and hepatic steatosis in the progres-
sion of chronic hepatitis C [16]. Several recent studies
have shown variable responses for interferon IFN-riba-
virin combination therapy, oxidative stress/steatosis and
insulin resistance due to the amino acid substitutions in
the HCV Core region [26,31-33]. Since, there is no pre-
vious report linking amino acid variations to oxidative
stress in a genome-specific manner, additional studies
are needed to identify the contribution of these substitu-
tions to the HCV induced pathogenesis.
We silenced Core gene using siRNA to further con-
f i r mt h er o l eo fH C V3 aC o r eg e n ei nH C Vi n f e c t i o n
and stimulation of cellular genes. RNAi activity directed
against multiple target sequences of the HCV genome
has been found to block effectively the synthesis of
replicon RNA [17,34]. We observed efficient inhibition
of HCV Core by siRNA against this functionally impor-
tant region of HCV 3a genotype. Protein expression
analysis revealed suppression of HCV Core protein
levels by 90% in Csi27, while suppression by Csi352
siRNA was 76% (Figure 4). Two different groups have
used siRNA against Core gene of HCV 1a and 1b geno-
type and observed 60% and 80% reduction in mRNA
and protein expression, respectively [34,35]. Silencing of
HCV Core through Core specific siRNA resulted in
reduced expression of host cellular genes Cox-2, iNOS
and VEGF in Core transfected Huh-7 cells at both
mRNA and protein levels. The significant inhibition of
Core mRNA in siRNA transfected cells also resulted in
50% reduction in PGE2 production and cell prolifera-
tion. The ability of Core siRNAs to inhibit HCV expres-
sion correlates well with the established role of HCV 3a
Core gene in oxidative stress and angiogenesis by regu-
lating these genes.
HCV Core up-regulate Cox-2 levels that correlated
with genes involved in HCV pathogenesis. Since the
inhibitors of Cox-2, such as siRNAs and celecoxib
showed an inhibition of cell proliferation and carcino-
genesis, we used Cox-2 specific siRNA to determine its
effect on gene expression. Cox-2 specific siRNA
(COXsi) significantly decreased the expression of not
only the Cox-2 itself but also the expression levels of p-
Akt, iNOS and VEGF. These results suggest that Cox-2
pathway is involved in mediating the activation of p-
Akt, iNOS and VEGF in HCV Core expressing cells
(Additional file 1 and Additional file 2, Figure S1).
Additionally, we explored whether HCV Core induced
Cox-2 gene, which in turn activated Akt (phosphryla-
tion), iNOS, and VEGF or it has a direct role in activat-
ing cellular genes understudy. We observed significant
reduction in the expression of Core and these genes
when treated with Csi27 and COXsi in combination at
both mRNA and protein levels (Figure 5). The signifi-
cant inhibition of Core and Cox-2 mRNA in siRNA
transfected cells either alone or in combination also
resulted in reduced PGE2 production and cell prolifera-
tion to 50%, 65% and 85%, respectively (Additional file 1
and Additional file 3, Figure S2). The reduction of these
genes by both HCV Core and Cox-2 siRNA indicate
that HCV Core is involved in HCV pathogenesis not
only by exerting its effect through Cox-2 signaling but is
also directly involved in the regulation of gene expres-
sion. Zhao et al., (2007) observed reduced production of
PGE2 and VEGF level in treated Huh-7 cells, and sup-
pressed HCC-associated angiogenesis in vitro and in
vivo using Cox-2 siRNA [20].
Most of the studies are conducted in Huh-7 derived
cell lines and with replicons supporting HCV RNA tran-
scription and protein synthesis. Recently, different
groups have studied the HCV replication in serum
infected liver cell lines [17,36-39]. In order to confirm
above results, we infected Huh-7 cells with native viral
particles from HCV genotype 3a positive serum, the
most prevalent type in Pakistan using already established
protocol [37,40]. Previously in our laboratory, Khaliq et
al., 2010 infected Huh-7, HEK, MDBK and HeLa cell
line with HCV 3a infected serum and observed that
MDBK and HeLa cell lines did not support HCV infec-
tion [41].
The current therapies against HCV have limited effi-
cacy due to the development of viral resistance and
HCV high mutation rate. The problem of viral mutants
could be resolved by using a mixture of siRNAs against
different sequences. Several studies have also demon-
strated the feasibility of targeting host cellular and viral
factors involved in HCV infection as potential targets
for therapy either alone or in combinations of both like
Lamin A/C, Caspase-8, Hsp90 and HCV genes [42-47].
T h ee f f e c to fH C Vs e r ao nt h ee x p r e s s i o no fC o x - 2 ,
iNOS and VEGF genes and their inhibition by siRNA
against HCV Core and host gene Cox-2 was also
observed. The expression of Cox-2, iNOS and VEGF
genes both at mRNA and protein levels were found to
be more stimulated in Huh-7 cells infected with HCV
3a serum as compared to HCV 1a (Data shown in Addi-
tional file 1 and Additional file 4, Figure S3). These
results were consistent with our HCV Core over-expres-
sion studies. We observed HCV replication in the Huh-
7 cells through detection of 5’UTR by Real-Time PCR
in cells at 3
rd and 5
th day post-infection and 92% reduc-
tion with Csi27, 83% with COXsi and 95% inhibition
when both siRNAs were used (Figure 7). At the day 3
rd
post infection, we observed that the decline of viral titer
using Core and Cox-2 siRNA in liver cells also reduced
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et al., has reported that siRNA against HCV Core and
5’UTR effectively blocked HCVr e p l i c a t i o ni ns e r u m
infected Huh-7 cells [40]. Many authors have observed
and also correlated amino acid substitution in Core in
HCV infected patient’s samples with steatosis, interferon
response, insulin resistance and oxidative stress. HCV
structural proteins play a direct role in the development
of liver steatosis and increase the risk of liver cancer in
transgenic mice [48-50]. In transgenic mouse model,
expressing HCV structural proteins produced profound
liver damage leading to hepatocellular carcinoma. Mor-
iya et al., (1997) reported that transgenic mouse model
expressing HCV Core protein showed hepatic tumor,
lipid accumulation in 16 months old mice [51]. Trans-
genic mice with steatosis displayed dysplastic growth of
cells evolving into tumor formation. Furthermore, trans-
genic mice showed deposition of collagen and progres-
sive fibrosis [52]. In our study, we observed high
expression of oxidative stress related genes in patients
infected with HCV genotype 3a as compared to 1a. In
future, the correlation of amino acid substitutions are
need to be address in transgenic mouse model or the
other natural victim of HCV that is chimpanzee to con-
firm our results and the full understanding of the
pathogenesis.
Conclusions
In conclusion, these studies for the first time suggest an
interaction of HCV 3a Core and Cox-2 in regulating the
genes involved in HCV pathogenesis which may provide
a better understanding for genome-specific mechanisms
involved in disease progression regulating Cox-2, pAkt,
iNOS, PGE2 and VEGF expression directly or indirectly.
Another outcome of these studies is the viral titer
reduction observed with combined gene silencing of
HCV Core and Cox-2, which support the idea of dual
strategy against both the viral and host genes to be a
potent approach in the treatment of chronic hepatitis C.
Methods
Patient’s Samples
The local HCV 3a and 1a patient’s serum samples used in
this investigation were collected from CAMB (Center for
Applied Molecular Biology) Diagnostic Laboratory,
Lahore, Pakistan after clinical diagnosis. ELISA and PCR
positive samples were stored at -80°C prior to RNA
extraction. The genotyping and quantification was per-
formed as previously described by Ahmad et al., (2010)
[3]. None of the subjects had received antiviral therapy.
Subjects with clinical evidence of HBV, diabetes and any
other type of cancer were excluded from study. The sub-
ject population with chronic HCV infection, viral load >
2×10
8 IU/ml of genotype 1a and 3a were included in this
study. Blood samples from three control and six HCV
positive patients for viral serum inoculations were taken
and immediately stored at -20°C. For expression of oxida-
tive stress related genes, three normal and six HCV posi-
tive liver biopsies and their blood samples were also
collected from Jinnah Hospital Lahore, Pakistan. Study
was approved from the Institutional Ethical Committee
and patient’s written consent was obtained.
RNA Isolation from Blood and Biopsy Samples
Total RNA from liver biopsies was extracted by using Qia-
gen RNeasy Mini kit (Qiagen, USA). For PBMCs, TRIzol
reagent (Invitrogen, Carlsbad, CA) was used according to
manufacturer’s protocol. Briefly, first the white blood cells
(PBMC) were separated from blood collected in anticoa-
gulant (EDTA) tube. For the lysis of erythrocytes 900 μlo f
RBC lysis solution (Gentra USA) was added in 300 μlo f
whole blood. The resulting mixture was incubated at
room temperature for 10 minutes and then, centrifuged at
1000 rpm for 1 minute at 4°C. The same step was repeated
unless PBMC formed a tight white pellet at the bottom of
the tube. Then Trizol reagent (Invitrogen, Carlsbad, CA)
was used for the isolation of RNA from these cells accord-
ing to manufacturer’s protocol.
Plasmid Construction
Viral RNA was isolated from thawed 100 μl serum ali-
quots using Gentra RNA isolation kit (Gentra System
Pennsylvania, USA) according to the manufacturer’s
instructions. 100-200 ng extracted viral RNA was used
for RT PCR using the SuperScript III one step RT-PCR
system (Invitrogen). HCV complementary DNA (cDNA)
encoding the full length Core protein (amino acid 1-191
of HCV isolates of HCV 3a genotype) were amplified
using Core specific primers. The PCR conditions were
9 4 ° C3m i n ;9 4 ° C3 5s e c ;5 8 ° C4 5s e c ;7 2 ° C1m i nf o r3 5
cycles and final extension at 72°C for 10 min. PCR pro-
duct was cloned into pCR3.1 mammalian expression
plasmid with FLAG tag inserted at the 5’ end with
restriction sites EcoRV and Xba1 (Fermentas, USA).
Similarly, The plasmid HFL (a kind gift provided by Dr.
Zafar Nawaz University of Miami, USA) containing full
length of HCV 1a was used as the template for PCR and
later cloning of HCV 1a Core in pCR3.1 mammalian
expression vector (Figure 1A). Sequencing was performed
for both expression plasmids by DNA Core facility at
CAMB, Lahore, Pakistan. Accession number for HCV 3a
Core sequences submitted to NCBI is EU266536.
Cell Culture
Huh-7 cell line (kindly provided by Dr. Zafar Nawaz,
University of Miami, USA) was maintained in 75 cm
2
culture flasks (Iwaki, Japan) containing DMEM (Sigma
Aldrich, USA) supplemented with 100 μg/ml penicillin/
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Page 9 of 13streptomycin, and 10% FBS as complete culture media
(CCM) (Sigma Aldrich, USA), at 37°C with 5% CO2.
The CCM was renewed every 3
rd day and cells were
passaged every 4-5 days. Viable cells were counted using
0.5% trypan blue (Sigma Aldrich, USA).
Transient Transfection
Approximately 5×10
5 Huh-7 cells were seeded into 6-
well tissue culture plates, at 24 hrs prior to transfection.
Huh-7 cells were transiently transfected with and with-
out expression plasmids (0.4 μg) of HCV Core 1a and
3a genotype in serum-free media using Lipofectamine™
2000 (Invitrogen) according to the manufacturer’s proto-
col. After 6 hours incubation at 37°C in 5% CO2, cells
were washed with 1× PBS and CCM was added to the
cells. Cells were harvested at 48 hrs post-transfection
for genes expression analysis by Real-Time PCR and
western blot analysis.
Design and Synthesis of siRNA
The DNA sequencing facility at CAMB Lahore, Pakistan
carried out sequencing of the Core gene of local HCV 3a
patient’s from serum samples. These sequences were
aligned using the software CLUSTAL_W option of
MEGA v.3.1. siRNA against HCV 3a Core and Cox-2
were designed to the most conserved target region using
the Ambion’s siRNA design tool http://www.ambion.
com/techlib/misc/siRNA_tools.html (Table 1) and did
not show any homology to other known human genes. A
negative control siRNA (scrambled siRNA) was designed
using scrambled sequences (Table 1). siRNA were
synthesized using Ambion’s siRNA silencer kit according
to the manufacturer’s instructions (Ambion, USA).
Viral Inoculation
Huh-7 cell line was used to establish the in vitro replica-
tion of HCV. Cell culturing and viral inoculations were
conducted as published previously [37,40]. High viral
titer (> 1×10
8 IU/ml) from HCV 3a and 1a patient’s was
used as principle inoculums in these experiments. Huh-
7 cells were maintained in 6-well culture plates, as
described above, to semi-confluence in CCM, washed
twice with serum-free medium, then inoculated with
500 μl( 5×1 0
7 IU/well) of HCV 3a and 1a infected
patient sera and 400 μl serum free media. Cells were
maintained overnight at 37°C in 5% CO2. The next day,
adherent cells were washed three times with 1× PBS,
the CCM was added and incubation was continued for
another 48 hrs. Cells were harvested and viral RNA in
Huh-7 cells assessed qualitatively by Real-Time PCR.
RNA Interference
To examine the effects of HCV Core and Cox-2 genes
on cellular gene expression, cells were transfected with
Core and Cox-2 specific or scrambled siRNAs. Briefly,
cells were seeded in 6-well (5×10
5/well) plates and cul-
tured in CCM until they became 60-80% confluent.
Cells were transiently transfected with 10, 20, 40 μM/
well of specific siRNAs (Csi27, Csi352 and COXsi either
alone or in combination) or scrambled siRNA along
with 0.4 μg of HCV Core 3a in serum free media using
Lipofectamine™ 2000 (Invitrogen) according to the
manufacturer’s protocol. After 6 hrs incubation at 37°C
in 5% CO2,C C Mw a sa d d e dt ot h ec e l l s .C e l l sw e r e
then harvested for gene expression and protein analysis
after 48 hrs. Protein analysis was carried out for above
mentioned experiments in 6-well plates.
For HCV infected experiments, Huh-7 cells were
seeded in 6-well plates as described above and cells
were infected with HCV infected serum (see Viral
Inoculum section for details). To analyze the effect of
siRNA on HCV infection, serum-infected Huh-7 cells
were seeded after three days of infection in 6 well plates
and grown to 80% confluence with 2 ml of standard
medium. This was followed by transfection of infected
cells with or without 40 μM/well of Csi27 and COXsi
siRNA either alone or in combination. Cells were
Table 1 Sequences of primers and target siRNAs
Primers used in vector construction
Core3a-sense ATGAGCACACTTCCTAAACC
Core3a-antisense CATGGCTGCTGGATGAATTA
3aCore-sense GCGATATCATGAGCACACTTCCTAAA
3aCore-antisense AATCTAGATCATGGCTGCTGGATGAAT
1aCore-sense GCGATATCAGCACGAATCCTAAAGGT
1aCore-antisense AATCTAGATTAGG CTGAAGCGGGCACGGT
Primers used in Real-Time PCR
RTp3.1-sense GGACGACGATGACAAGGACT
RT1a-antisense GGGGAGACAGGA GCCATC
RT3a-antisense GGCTGTGACCGTTCAGAAGT
Cox-2-sense AACCCACTCCAAACACAG
Cox-2-antisense CTGGCCCTCGCTTATGATCT
iNOS-sense CACCTTGGAGTTCACCCAGT
iNOS-antisense ACCA CTCGTACTTGGGATGC
VEGF-sense CTTGCCTTGCTGCTCTACC
VEGF-antisense CACACAGGATGGCTTGAAG
GAPDH-sense ACCACAGTCCATGCCATCAC
GAPDH-antisense TCCACCACCCTGTTGCTGTA
siRNAs used for silencing
Csi27-sense AAGGATGGTGTTTCTTTTGGTCCTGTCTC
Csi27-antisense AAACCAAAAGAAACACCATCCCCTGTCTC
Csi352-sense AAATCGATGACTTTACCCAAACCTGTCTC
Csi352-antisense AATTTGGGTAAAGTCATCGATCCTGTCTC
Scramble-sense AAGTCGAGTCGCGTATGCAGGCCTGTCTC
Scramble-antisense AACCTGCATACGCGACTCGACCCTGTCTC
COXsi-sense AATTATTTCTGAAACCCACTCCCTGTCTC
COXsi-antisense AAGAGTGGGTTTCAGAAATAACCTGTCTC
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Real-Time PCR and viral load determination as
described below.
Cell Proliferation Assay and PGE2 Measurements
Approximately 2×10
3 Huh-7 cells were seeded into 96-
well tissue culture plates for 24 hrs prior to transfec-
tion. Huh-7 cells were transiently transfected with 0.1
μg / w e l lo fH C VC o r e1 aa n d3 ap l a s m i d sw i t ha n d
without Core and Cox-2 siRNA in serum-free media
using Lipofectamine™ 2000 (Invitrogen) according to
the manufacturer’s protocol. After 6 hrs incubation at
37°C in 5% CO2,C C Mw a sa d d e dt ot h ec e l l s .T h e
MTT colorimetric assay was performed to detect cell
proliferation after 24 hrs and 48 hrs of incubation. The
absorbance of resulting formazan crystals (solubilized
with DMSO) was read at 590 nm on ELISA plate
reader. PGE2 levels were also determined in Huh-7
cells using above cell culture/transfection conditions
and assayed with the Biotrak Prostaglandin E2 Enzyme
Immunoassay system (Amersham Pharmacia Biotech,
USA) according to the manufacturer’s protocol at 459
nm wavelength.
Viral Load
Viral RNA was isolated using Gentra RNA isolation kit
(Gentra System Pennsylvania, USA) according to the
manufacturer’s instructions. For viral quantification
Sacace HCV quantitative analysis kit (Sacace Biotechnol-
ogies Caserta, Italy) was used. Briefly, 10 μlo fe x t r a c t e d
viral RNA was mixed with an internal control derived
from 5’UTR provided by Sacace HCV Real TM Quant
kit and subjected to viral quantification using Real-Time
PCR Smart Cycler II system (Cepheid Sunnyvale, USA).
For protein expression analysis at day 3
rd of viral inocu-
lation, cells were washed 3 times before harvesting and
Western blotting was performed.
Real-Time PCR
For gene expression analysis, total RNA from Huh-7
cells transiently transfected with mock, HCV Core 1a
and 3a was extracted using TRIzol Reagent (Invitro-
gen, USA). cDNA was synthesized using 1 μgo ft o t a l
RNA with SuperScript III Kit (Invitrogen, USA).
Gene expression analysis was carried out using Real
Time PCR ABI 7500 system (Applied Biosystems Inc,
USA) with SYBR Green mix (Fermentas, Canada)
using gene specific primers (see Table 1). PCR condi-
tions were as follow: 95°C, 30 sec; 58°C, 30 sec and
extension at 72°C for 45 sec, 40 cycles. The relative
gene expression analysis was carried out using the
“SDS 3.1 software” (provided by Applied Biosystems
Inc, USA). GAPDH was used as internal control for
normalization.
Western Blotting
Transfected and infected cells were lysed with Proteo-
JET mammalian cell lysis reagent (Fermentas, Canada).
Equal amounts of total proteins were subjected to elec-
trophoresis on 12% SDS-PAGE and electrophoretically
transferred to a nitrocellulose membrane using manu-
facturer’s protocol (Bio-Rad, USA). Blots were incubated
with specific-monoclonal antibodies of HCV Core, Cox-
2, VEGF, p-Akt and GAPDH (Santa Cruz Biotechnology,
Inc, USA). Proteins expression was evaluated using Che-
miluminescence’s detection kit (Sigma Aldrich, USA).
For protein quantifications X-ray films were scanned
and fold inductions were calculated by densitometer
analysis.
Statistical Analysis
All statistical analysis was performed by using SPSS soft-
ware (version 16.0, SPSS Inc). Data are presented as
mean ± SD. Numerical data were analyzed using stu-
dent’s t-test and ANOVA. P value < 0.05 was considered
statistically significant.
Additional material
Additional file 1: Supplemental Results. This file contains three
experimental results as supporting data and has been mentioned in the
text.
Additional file 2: Figure S1. Silencing of host cellular gene, Cox-2
show reduction in the expression of genes involved in HCV
pathogenesis. Huh-7 cells were transfected with HCV-3a Core expression
vector or mock-treated along with or without 10 μM, 20 μM and 40 μM
of Cox-2 siRNAs for 48 hrs. (A) Cox-2 siRNA (COXsi) reduced gene
expression of Core induced Cox-2 measured through semi-quantitative
PCR. (B) Silencing of Cox-2 gene at protein expression level was
determined by Western blot analysis after 48 hrs transfection with mock
(M), with and without siRNA (COXsi) and scramble siRNA (SC) in Huh-7
cells. Protein levels for GAPDH gene are also shown as internal control.
(C) Effect of silencing of Cox-2 gene on the relative gene expression
levels quantified by Real-Time PCR 48 hrs post transfection are shown as
fold induction for Cox-2/iNOS/VEGF genes. GAPDH was used as internal
control for normalization. Three independent experiments were
performed having triplicate samples. Error bars indicate, mean S.D, *p <
0.01 verses Core.
Additional file 3: Figure S2. Combined effect of Cox-2 and HCV 3a
Core siRNAs on intracellular PGE2 production and the Huh-7 cells
proliferation. (A) Intracellular level of PGE2 was determined in Core
transfected cells with and without Core, Cox-2 and in combination of
both siRNAs, using Biotrak prostaglandin Enzyme immunoassay system
according to manufacturer’s protocol. (B) Inhibition of Huh-7 cells
proliferation was observed in Core transfected cells with and without
Core, Cox-2 and in combination of both siRNAs by using MTT assay.
Three independent experiments were performed having triplicate
samples. Error bars indicate mean S.D, *#p < 0.001, *p < 0.01 verses Core.
Additional file 4: Figure S3. HCV 3a sera infection increases
expression of genes involved in HCV pathogenesis as compared
with HCV 1a sera. (A) Huh-7 cells were infected with high titer sera
samples from HCV patients, either HCV-3a or HCV-1a genotype for 72 hrs.
RNA expression levels as relative fold induction to normal sera are shown
for Cox-2, iNOS and VEGF genes. (B) The protein expression levels were
determined by Western blot analysis from Huh-7 cell lysates infected
with HCV-1a (S1a), 3a (S3a) serum compared to normal and effect on
Cox-2, VEGF and p-Akt expression using specific antibodies. Protein levels
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Page 11 of 13for GAPDH gene are shown as internal control. Three independent
experiments with triplicate determinations were performed. Error bars
indicate mean S.D, * p < 0.01 verses serum 1a.
List of abbreviations
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